This article considers the pricing policy for pharmaceuticals in Australia which is widely seen as having achieved low drug prices. However compared to New Zealand the evidence implies that it might have improved its performance significantly if it had proactively sought market best pricing. The Australian record suggests that the information sought by authorities may not be sufficient for optimal pricing and that the economic evaluation of pharmaceuticals may be neither necessary nor sufficient for achieving this goal.
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Introduction
Huge variation in per capita expenditures for pharmaceuticals exists across countries. In 2007 the USA spent 1 .9% of its GDP on pharmaceuticals or about 27% more than the OECD average of 1.5% which, in turn, was 25% above the figure for Australia, a country which has historically boasted low pharmaceutical costs and prices. But the Australian figure of 1.2% of GDP was 33% above New Zealand"s 0.9%. In absolute terms the US spent $878 per capita in 2007, 104% and 164% more than Australia and New Zealand respectively. Despite this life expectancies in these latter two countries are 2.3 and 2.1 years longer than in the USA and infant mortality in the USA is 40% and 60% higher than in New Zealand and Australia respectively. Cancer rates in the three countries are virtually identical; the USA has marginally lower mortality from stroke but higher mortality from ischemic heart disease. Prima facie, therefore, the lower drug expenditures in Australia and New Zealand do not result in obviously poorer health.
In this article, however, we focus upon expenditures and upon one of its two determinants, namely the prices paid for drugs. The interesting policy question is whether or not the present Australian system results in lower prices. While a counterfactual system cannot be evaluated it is possible to assess the success of the Australian approach by selective comparisons. We illustrate this below using publicly available data.
Surprisingly few studies of pricing have been published. In 2001, the Australian Productivity Commission released the most comprehensive report to date [1] . This compared the prices received by manufactures for a basket of 150 of the top-selling PBS medicines ranked by total expenditure with seven comparator countries, namely, the United States of America (USA), Canada, the United Kingdom (UK), France, Spain, Sweden and New Zealand (NZ). Overall the report concluded that there is "some evidence to support the view that Australia"s costcontainment arrangements may have contributed to keeping prices relatively low".
Since then a number of bilateral and multilateral international price comparisons have been published relevant to Australia [2, 3, 4, 5, 6,] . Overall it can be concluded from these references that Australia does indeed pay prices in the mid to low end of the reported range. However, the obvious question is "compared to what"? Historically Australian analysts have only been interested in price comparisons within the Organisation for Economic Cooperation and Development (OECD) countries and particularly with the USA. However the cost of pharmaceuticals to a nation is so great that it justifies a more careful examination of the data and a more focused question than the one implicit in such reviews. Analogously, almost any OECD country which compares its health system with the USA health system could conclude that its system performs well. But the conclusion is not justified as the comparison is too limited and the implied criterion inappropriate. The question should not be whether Australia performs relatively well overall but whether there is evidence from any country that we could do better. The appropriate comparator is not average performance but best performance and not of the overall scheme but of any part where improvement is possible.
To illustrate the importance of this point, a case study is presented which compares the prices of a basket of drugs from Australia to the same drugs in NZ, which enjoys some of the lowest prices for pharmaceuticals in the OECD. The analysis is then extended to make a comparison with the "world market".
Background
Australia's PBS: The Australian Pharmaceutical Benefits Scheme (PBS) provides subsidised medicines for all Australians. The prices paid to manufacturers for medicines listed in the PBS "market" are negotiated by the Government following a positive recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC), an independent statutory body which was the first in the world to require the inclusion of an economic evaluation for a drug to be listed (and therefore subsidised) by the PBS. When a competitive generic drug is first introduced (following expiry of a patent) the price proposed by the competitor is revealed to the original manufacturer which then has the option of reducing its own price. In addition to the negotiated price there is some scope for allowing market forces to influence the prices paid for generic pharmaceuticals (see Box 1 below: Minimum Pricing Policy).
Box 1: Minimum Pricing Policy
The minimum pricing policy was introduced in 1990 and was designed to increase price competition in the PBS market by allowing manufacturers some latitude in setting prices for medicines listed on the PBS. It allows the Commonwealth Government to base the reimbursement price, known as the benchmark price, on that of the lowest priced brand "which is reasonably available in the marketplace". Sloan C (1995). A history of the Pharmaceutical Benefits Scheme 1947-1992. Commonwealth of Australia, Canberra.
More information can be found at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-pbpapolicies-contents New Zealand's PHARMAC: New Zealand has a relatively small population compared to Australia (4 versus 22 million people). It has similar levels of regulation and government intervention in health care but it uses a competitive tender process to purchase almost half of the medicines listed on the Pharmaceutical Management Agency (PHARMAC) National Schedule [7] . Unlike the Australian scheme information concerning a competitor"s bid is not provided to the original manufacturers or to other competitors. It has been argued that the use of a competitive tender process undermines the reliable supply of drugs for the population, and limits the number of drugs available on the formulary [8] . Others have identified benefits [9, 10] . A smaller range of drugs on a formulary per se does not necessarily mean poorer health or even a significantly reduced set of therapeutically important drugs for the population, as argued by the World Health Organisation (WHO) in support of its Model Drug List [11] . More importantly, competitive tender per se does not determine the price at which drugs will be rejected. A relatively less wealthy country like NZ may rationally adopt a more stringent evaluation than a relatively wealthier country. This is a separate issue to the question concerning the price of drugs which have been purchased.
Methods
For the present comparison, data were obtained for the 50 highest cost subsidy items in Australia for the 12 months to 30 June 2007 [12] . Items were matched for the corresponding item listed in the December 2007 NZ Pharmaceutical Management Agency (PHARMAC) schedule [13] on drug, form, strength and pack size. This allows calculation of the total difference in overall cost with the comparators, taking into consideration both the price of the item and the volume that was dispensed in Australia. This does not take into consideration any discounts given to pharmacies by manufacturers or wholesalers, and does not include dispensing fees and charges.
International Prices
The NZ comparison is then extended using the International Drug Price Indicator Guide (2007) [14] . This is an annual publication produced by the not-for-profit organisation Management Sciences for Health, in collaboration with the World Health Organisation (WHO), and with funding from the United Kingdom Department for International Development (DIFD). It is designed as a reference with which to compare current prices paid for items on the international market. The prices in this database are from both suppliers and buyers, and include government agencies, not-for profit organisations and international development organisations. Only nine items could be matched with the Australian basket of 50 most expensive medicines (by volume) for the International Drug Price Indicator Guide, which reflects the heavy reliance of lower income countries on off-patent generic drugs, as they are less able to afford many of the patented medicines which appear heavily in the Australian Top 50.
Results

New Zealand Prices
There were 34 matched items available for comparison, which are shown in Table 1 . Prices were adjusted for differences in pack sizes where applicable. Prices were adjusted using both the average monthly exchange rates from the Australian Taxation Office [15] and Purchasing Power Parity ratios reported by the OECD [16] . Using both methods achieved very similar results and both are presented in Table 1 . This indicates that NZ achieved lower prices for 29 of the 34 matched drugs. A two sided test of mean values rejected the null hypothesis that there is no difference between matched prices at the 5% significance level (p=0.02). The data were used to calculate the savings to Australia if it had matched the NZ drug prices. The total cost of the 50 items in Australia in 2007 was $Aus 2.62 billion [12] . If the Australian Government bought 34 of those 50 items at the NZ price, it would have saved $Aus 0.93 billion (0.87 using PPP methodology) over one year. This implies that Australia paid 51.4% more for these items despite its greater market strength.
If the comparison is limited to the generic medicines in Table 1 , Australia would have achieved a $Aus 460 million saving. The result support a comparison of the prices paid in NZ with 11 other countries in which NZ prices were at the lower end of the spectrum [5] .
International Prices
These comparisons are reported in Table 1 alongside the NZ prices. Using the same methodology as above, if Australia had achieved the prices paid internationally for nine of those items it would have saved $Aus 0.22 billion. Where comparisons were available for each of the Australian, NZ and International guides, NZ was much closer than Australia to the international prices, particularly for items for which generics are available.
Although this is not an exhaustive comparison it does suggest that NZ, rather than being the "low paying outlier", has managed to take advantage of global competition through its competitive tendering process and may pay closer to "world best price".
Discussion
One of the key objectives of the National Medicines Policy of Australia, and of many countries worldwide, is "timely access to the medicines that the population needs, at a cost individuals and the community can afford" [17] . The available data suggests that despite significantly lower prices than in the USA and the OECD Australia pays significantly more for many of its drugs than is necessary.
In a textbook competitive market, global prices would be similar with some variation because of the market share of the buyer. However, in the case of NZ, the population is smaller than in most other OECD countries including Australia, and the price differential cannot be the result of greater purchasing power. A second possibility is that NZ"s lower prices are attributable to poorer, less safe products. However, the question of quality is not relevant to our case studies. All the drugs discussed met the regulatory requirements in both Australia and NZ, or in the case of drugs on the International Drug Price Indicator Guide, the standards of the WHO. There are therefore strong reasons for believing the price differences reflect the institutions and institutional histories of the buying authorities and that, Australia"s higher prices are attributable to its ignoring of relevant comparators and a failure to negotiate as forcefully as its small pacific neighbour.
The differences attributable to the different institutional approaches are not small and may, or may shortly, amount to 20% more of the annual government drug bill. With rising health expenditures there is a strong case for efficient pricing. Evidence of potential savings with respect to generic drugs is particularly important because of the number of high cost, high volume medicines due to come off patent in the near future. One example is the lipid lowering drug atorvasatin which, by itself accounted for 7.6% of the Australian Government drug expenditures in the 12 months to June 2007 [12] . As the pharmaceutical market becomes increasingly global, there is no reason for limiting price comparisons to similar rich countries. The Indian generic giant Ranbaxy has recently entered the Australian PBS market without any greater concern over the quality of its products than with the hi-tech products on the world market that are produced in lower income countries.
The results presented here suggest the need for a review of Australia"s drug pricing procedures. As argued by Bulfone [18] the evidence suggests that competition, particularly by closed tender, will produce better results than Australia"s largely administrative approach. Especially in the offpatent generics market, there should be an examination of the prices paid in all of the countries using quality generic products. As a minimum, countries should compare prices paid for generics with those paid in India. The failure to include countries and organisations outside the OECD group of nations from a price comparison, if products meet the relevant quality benchmarks, is not justified. Results from the case study presented argue that potential cost savings could justify the effort required.
Some argue that richer nations should pay more for innovative drugs to support ongoing research and development into newer compounds [19] whilst others take the opposing view [20] .
In the case of generic drug prices the argument is particularly weak. However, this is a separate issue. If it is concluded that the world"s most profitable industry should, uniquely, receive higher prices then this should at least be public information and policy should be based upon a full examination of the available evidence.
Conclusions
The data presented here adds to the evidence that the economic evaluation of pharmaceuticals is neither necessary nor sufficient for price control. Australia was the first country to introduce mandatory economic evaluation of drugs, which it did in January 1993. At the time the expected results of this were not made explicit but it was widely believed that the move would help to control the price of drugs. In recent years relative Australian prices have risen. Data in the present article show that it is possible to obtain lower prices in the absence of economic evaluation through a more aggressive use of market opportunities.
The results here also highlight an asymmetry in the criteria used in the two stages of a drug evaluation. Since the advent of evidence-based medicine, clinicians have been aware that the choice of the comparator for a treatment or intervention can have important implications for the assessment of differences. In Australia and elsewhere, authorities have specific guidelines for pharmaceutical evaluations with regard to the choice of comparator. By contrast, it appears that the importance of this has yet to be discovered by economic advisors, who have allowed prices to be significantly above the known price of comparators in other parts of the market.
